Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Saint Mary's Hospital
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Saint Mary's Hospital
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence St. John
mi
from
Southfield, MI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence St. John
mi
from
Southfield, MI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Saint Joseph's Hospital
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Saint Joseph's Hospital
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Diagnostic and Treatment Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Diagnostic and Treatment Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Rocky Mountain Oncology
mi
from
Casper, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
mi
from
Casper, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop
The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop
The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)
A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)
A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Lancanster Cancer Center
mi
from
Lancaster, PA
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Updated: 1/1/1970
Lancanster Cancer Center
mi
from
Lancaster, PA
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
University Of Tennesse Cancer Institute
mi
from
Memphis, TN
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Updated: 1/1/1970
University Of Tennesse Cancer Institute
mi
from
Memphis, TN
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Loyola University Medical Center
mi
from
Proviso, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
mi
from
Proviso, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL